References
S-163

1. InterQual® Level of Care Criteria. 2017. Acute Care Adult. McKesson Health Solutions, LLC.

2. Unukovych D, Sandelin K, Liljegren A, et al. Contralateral prophylactic mastectomy in breast cancer patients with a family history: A prospective 2-years follow-up study of health related quality of life, sexuality and body image. *Eur J Cancer.* 2012 Jun 11. [Epub ahead of print].

3. Bayraktar S, Elsayegh N, Barrera A, et al. Predictive Factors for BRCA1/BRCA2 Mutations in Women With Ductal Carcinoma In Situ. *Cancer.* 2012 Mar 15;118(6):1515-22.

4. Portschy P, Tuttle T. Contralateral prophylactic mastectomy: perceptions versus reality*. Ann. Intern. Med*. 2013 Sep 17;159(6):428-9.

5. Nestle-Kramling C, Kuhn T. Role of breast surgery in BRCA mutation carriers. *Breast Care.* 2012;7(5):378-382.

6. Schwartz M, Isaacs C, Graves K, et al. Long term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. *Can.* 2012;118(2):510-517.

7. Cooke R, Jones ME, Cunningham D, et al. Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. *Br J Cancer.* 2013;108(11):2399-2406.

8. Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. *Breast Cancer Res T*reat. 2013 Jul;140(1):135-42.

9. Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. *J Natl Cancer In*st. 2014 Jul 16;106(8).

10. Metcalfe K1, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ.* 2014 Feb 11;348:g226.

11. National Cancer Institute (NIH). Surgery to Reduce the Risk of Breast Cancer. Last updated August 12, 2013.

12. Burke EE, Portschy PR, Tuttle TM. Prophylactic Mastectomy: Who Needs it, When and Why. *J. Surg. Oncol*. 2015;11:91-95.

13. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutxler RK, et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. *Deutsches Ärzteblatt International*. 2011 May;108(19):323.

14. Heemskerk-Gerritsen B, Rookus M, Seynaeve C, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. *Int J Cancer* [serial online]. February 1, 2015;136(3):668-677.

15. Pesce C, Liederbach E, Wang C, Lapin B, Winchester D, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. *Ann Surg Oncol.* [serial online]. October 2014;21(10):3231-3239.

16. Kruper L, Kauffmann R, Smith D, Nelson R. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. *Ann Sur Oncol.* [serial online]. October 2014; 21(11):3448-3456.

17. Fayanju O, Stoll C, Fowler S, Colditz G, Margenthaler A. Contralateral Prophylactic Mastectomy after Unilateral Breast Cancer: A Systematic Review & Meta-Analysis. *Ann Surg*. 2014;260(6):1000–1010.

18. Metcalfe K, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ*. 2014;348:g226

19. National Cancer Institute. Surgery to Reduce the Risk of Breast Cancer. Reviewed August 12, 2013. http://www.cancer.gov/cancertopics/factsheet/Therapy/risk-reducing-surgery.

20. Boughey JC, Attai DJ, Chen SL, et al. Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. *Ann Sur Oncol*. 2016;23(10):3100-3105.

21. Chagpar A. Contralateral prophylactic mastectomy. In: Vora S (Ed). UpToDate. Waltham, Mass: *UpToDate 2017*. www.uptodate.com. Accessed on June 11, 2017.